Our results indicate that short-term expansion, together with IL-2 and IL-12 supplementation, enriches for HLA-DR+ CTLs, yielding PBMCs with superior cytotoxicity against BC cells, even at lower effector-to-target ratios. Here, IL2 is linked to breast cancer.